Author

Stephen Page

Stephen Page

Writer on DMT, ayahuasca, iboga and tryptamine research. LLB; incoming MSc in Psychedelics: Mind, Medicine and Culture, University of Exeter (2026)

When the Molecule Escapes the Plant: Iboga, Gabon and Who Benefits from Psychedelic Medicine

Exploration

When the Molecule Escapes the Plant: Iboga, Gabon and Who Benefits from Psychedelic Medicine

Gabon has spent years trying to protect iboga from extraction. But ibogaine can already be produced from other African plants, while modern drug development can move further still — into synthetic analogues and digital information.

August 28, 2026 · 15 min read

The Study That Became a Statute

Research

The Study That Became a Statute

How a 30-person ibogaine study moved through veteran philanthropy, Stanford, Silicon Valley biotech and US state legislatures — and why the money is only part of the story.

August 26, 2026 · 16 min read

Nichols Named the Experiment.

Nichols Named the Experiment.

Eight Years Later, Someone Ran It. A follow-up to Endogenous DMT in Humans: A Critical Review of the State of the Evidence. That piece surveys the evidential

August 22, 2026 · 10 min read

23 of 25

ARDMT Field Notes

23 of 25

A deep dive into the magnesium-ibogaine treatment. So What Does a 12-Month Ibogaine Study Actually Show?

August 21, 2026 · 9 min read

“You haven't taken psychedelics, so you can't understand.”

“You haven't taken psychedelics, so you can't understand.”

There's something obviously true about that. Someone who has taken DMT knows something about the experience that someone who hasn't simply doesn't.

August 21, 2026 · 1 min read

The Same Evidence, Different Bryan Johnson

Cabinet of Marginalia

The Same Evidence, Different Bryan Johnson

Bryan Johnson’s psychedelic claims seem to change depending on who is asking the question. On Theo Von’s podcast, psilocybin “legit is a longevity therapy.” In Johnson’s own more formal Blueprint write-up, the same experiment is described much more carefully: a high-dose p

August 20, 2026 · 8 min read

Before the Molecule

Ethics

Before the Molecule

The field's own meta-analysis found that therapy hours predict nothing in psychedelic trials. That is not a finding about therapy. It is a finding about the record.

August 16, 2026 · 27 min read

When the Shit Hits the Bridge

Cabinet of Marginalia

When the Shit Hits the Bridge

Or Southern Water can burst three sewage mains in a week, deploy a fleet of tankers to manage the flows, and drive one of them ...

August 13, 2026 · 9 min read

The Sensitive Period

Ethics

The Sensitive Period

Two studies of psychedelics and new motherhood are underway. One raised $103 million. The other raised $3,200. They are not asking the same question.

August 12, 2026 · 9 min read

Seventeen to One

Ethics

Seventeen to One

The field has begun to suspect that preparation is doing some of the work. Its consensus reporting standard gives the preparatory phase a single item.

August 10, 2026 · 12 min read

Thirty-Seven Pages, Posted from Amsterdam

Cabinet of Marginalia

Thirty-Seven Pages, Posted from Amsterdam

In 1874 a farmer in upstate New York privately printed a pamphlet about anaesthesia and circulated it himself. Almost no original copies can now be found. One of them changed William James's mind — and Harvard turns out to hold the archive where the hunt should start.

August 8, 2026 · 13 min read

Before the First Dose

Ethics

Before the First Dose

Twelve veterans with severe, treatment-resistant PTSD walked into a clinic in Ohio. Eleven weeks later, nine of them no longer met the diagnostic criteria for the condition that had, in most cases, defined a decade or more of their lives.

July 31, 2026 · 8 min read

← Return to homepage